[HTML][HTML] Complementary use of carbohydrate antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19. 9 Epitope) in gastrointestinal cancers: biological rationale towards …
R Indellicato, A Zulueta, A Caretti, M Trinchera - Cancers, 2020 - mdpi.com
Carbohydrate antigen 19.9 (CA19. 9) is used as a tumor marker for clinical and research
purposes assuming that it is abundantly produced by gastrointestinal cancer cells due to a …
purposes assuming that it is abundantly produced by gastrointestinal cancer cells due to a …
Retrospective evaluation of treatment response in patients with nonmetastatic pancreatic cancer using CT and CA 19-9
Background Imaging studies have limitations in evaluating pancreatic ductal
adenocarcinoma (PDAC) treatment response. Purpose To investigate the effectiveness of …
adenocarcinoma (PDAC) treatment response. Purpose To investigate the effectiveness of …
[HTML][HTML] CircRNA_000864 upregulates B-cell translocation gene 2 expression and represses migration and invasion in pancreatic cancer cells by binding to miR-361 …
L Huang, J Han, H Yu, J Liu, L Gui, Z Wu, X Zhao… - Frontiers in …, 2020 - frontiersin.org
Background Pancreatic cancer is a fatal disease with a very poor prognosis due to its
characteristic insidious symptoms, early metastasis, and chemoresistance. Circular RNAs …
characteristic insidious symptoms, early metastasis, and chemoresistance. Circular RNAs …
[HTML][HTML] LINC01006 promotes cell proliferation and metastasis in pancreatic cancer via miR-2682-5p/HOXB8 axis
L Zhang, Y Wang, L Zhang, G You, C Li, B Meng… - Cancer cell …, 2019 - Springer
Background Pancreatic cancer (PC) is one of the deadliest cancers about the digestive
system. Recent researches have validated that long non-coding RNAs (lncRNAs) play vital …
system. Recent researches have validated that long non-coding RNAs (lncRNAs) play vital …
[HTML][HTML] New insights into the biological response triggered by dextran-coated maghemite nanoparticles in pancreatic cancer cells and their potential for theranostic …
M Balas, D Predoi, C Burtea, A Dinischiotu - International Journal of …, 2023 - mdpi.com
Iron oxide nanoparticles are one of the most promising tools for theranostic applications of
pancreatic cancer due to their unique physicochemical and magnetic properties making …
pancreatic cancer due to their unique physicochemical and magnetic properties making …
NGRKC16-lipopeptide assisted liposomal-withaferin delivery for efficient killing of CD13 receptor-expressing pancreatic cancer and angiogenic endothelial cells
MMCS Jaggarapu, HK Rachamalla, NV Nimmu… - Journal of Drug Delivery …, 2020 - Elsevier
Cancer treatment necessitates targeted and efficient drug delivery to reduce drug-mediated
adverse collateral effects. We develop herein a new liposomal delivery system which targets …
adverse collateral effects. We develop herein a new liposomal delivery system which targets …
[HTML][HTML] Comparison of different Pancreatic cancer treatments: a three-year retrospective study in the oncology center of Tangier university hospital, Morocco
H Abrini, M Amzerin, A El Baaboua, S Aboulaghras… - BMC …, 2023 - Springer
Background Pancreatic cancer is among the most lethal malignancies, with a 5-year overall
survival (OS) of less than 10% for all stages. The present study aims to evaluate the …
survival (OS) of less than 10% for all stages. The present study aims to evaluate the …
Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy
Purpose To identify common and unique pre-treatment prognostic factors in patients with
borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma …
borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma …
[HTML][HTML] Equivalent efficacy but different safety profiles of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
IG Rapposelli, A Casadei-Gardini, C Vivaldi, G Bartolini… - Biomolecules, 2021 - mdpi.com
FOLFIRINOX (FFX) and gemcitabine+ nab-paclitaxel (GN) are the most common
chemotherapy regimens in first-line treatment of metastatic pancreatic cancer (PC). They …
chemotherapy regimens in first-line treatment of metastatic pancreatic cancer (PC). They …
[HTML][HTML] Prevention and treatment of digestive tract issues induced by postoperative adjuvant chemotherapy for pancreatic cancer using Terra Flava Usta
T Wu, T Jin - American Journal of Translational Research, 2021 - ncbi.nlm.nih.gov
Objective: To investigate the effects and possible mechanism of prevention and treatment of
digestive tract reactions to postoperative adjuvant chemotherapy for pancreatic cancer (PC) …
digestive tract reactions to postoperative adjuvant chemotherapy for pancreatic cancer (PC) …